Literature DB >> 158567

Suppressor T-cells in BCG-infected mice.

F M Collins, S R Watson.   

Abstract

Specific pathogen-free B6D2 hybrid mice were infected with high (10(8) cells, intravenous), moderate (10(6) cells, intravenous), and low 10(3) cells, aerogenic) doses of viable BCG Pasteur. The growth of the BCG in the lungs and spleens of the three groups was followed over a 90-day period and correlated with the level of tuberculin hypersensitivity. Spleen cells were harvested from the three groups of mice at increasing time intervals and filtered through nylon wool to remove adherent cells, and the level of blast transformation after exposure to phytohemagglutinin and purified protein derivative was determined. Early in the BCG infection both the high- and the intermediate-dose groups showed enhanced thymidine incorporation by the spleen cell cultures, followed by a profound depression late in the infection. At this time, both groups of mice were anergic to purified protein derivative injected into footpads. Cell mixing studies demonstrated the presence of a population of suppressor cells in the spleens of the anergic animals. The suppressive abilities of these cells would be ablated by treatment with anti-Thy-1 antiserum and complement. The aerogenically infected mice were unresponsive to purified protein derivative but showed no evidence of suppressor T-cells. The lack of tuberculin sensitivity in these mice seemed to be due to a lack of sensitized T-cells in the spleen rather than to active immunosuppression.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 158567      PMCID: PMC414479          DOI: 10.1128/iai.25.2.491-496.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  21 in total

1.  [Spleen reactivity after BCG treatement: test and strain dependency of the response].

Authors:  I Florentin; S Orbach-Arbouys
Journal:  Ann Immunol (Paris)       Date:  1977 Jan-Mar

2.  Active suppression of in vitro reactivity of spleen cells after BCG treatment.

Authors:  S Orbach-Arbouys; M F Poupon
Journal:  Immunology       Date:  1978-03       Impact factor: 7.397

3.  BCG-induced suppressor cells. I. Demonstration of a macrophage-like suppressor cell that inhibits cytotoxic T cell generation in vitro.

Authors:  G R Klimpel; C S Henney
Journal:  J Immunol       Date:  1978-02       Impact factor: 5.422

Review 4.  Cellular antimicrobial immunity.

Authors:  F M Collins
Journal:  CRC Crit Rev Microbiol       Date:  1978

5.  The effect of cultural conditions on the distribution of Mycobacterium tuberculosis in the spleens and lungs of specific pathogen-free mice.

Authors:  F M Collins; L G Wayne
Journal:  Am Rev Respir Dis       Date:  1974-08

6.  Transfer of delayed and Arthus sensitivity with blood plasma from x-irradiated guinea-pigs.

Authors:  F M Collins; A Volkman; D D McGregor
Journal:  Immunology       Date:  1970-09       Impact factor: 7.397

7.  PPD tuberculin--a B-cell mitogen.

Authors:  B M Sultzer; B S Nilsson
Journal:  Nat New Biol       Date:  1972-12-13

8.  Infection with Bacillus Calmette-Guérin activates murine thymus-independent (B) lymphocytes.

Authors:  B M Sultzer
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

9.  Development of suppressor T-cells in Mycobacterium habana-infected mice.

Authors:  S R Watson; F M Collins
Journal:  Infect Immun       Date:  1979-08       Impact factor: 3.441

10.  Immune response to persistent mycobacterial infection in mice.

Authors:  F M Collins; N E Morrison; V Montalbine
Journal:  Infect Immun       Date:  1978-05       Impact factor: 3.441

View more
  30 in total

1.  Regulation of herpes simplex virus-specific cell-mediated immunity by a specific suppressor factor.

Authors:  D W Horohov; J H Wyckoff; R N Moore; B T Rouse
Journal:  J Virol       Date:  1986-05       Impact factor: 5.103

2.  Scrub typhus vaccine candidate Kp r56 induces humoral and cellular immune responses in cynomolgus monkeys.

Authors:  Suchismita Chattopadhyay; Ju Jiang; Teik-Chye Chan; T Scott Manetz; Chien-Chung Chao; Wei-Mei Ching; Allen L Richards
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

3.  Induction by an immunogenic immunomodulating agent of nonspecific T cell suppression of lymphocyte responsiveness in MLR but not of antibody production.

Authors:  C Reuben; D Halperin; S Ben-Efraim; D W Weiss
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

4.  Mechanisms underlying the depressed production of interleukin-2 in spleen and lymph node cell cultures of mice infected with Mycobacterium bovis BCG.

Authors:  R Turcotte; D Legault
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

5.  Mycobacterium bovis, BCG, modulation of murine antibody responses: influence of dose and degree of aggregation of live or dead organisms.

Authors:  C A Brown; I N Brown
Journal:  Br J Exp Pathol       Date:  1982-04

6.  Thymus-dependent lymphocytes in leprosy. II. Effect of chemotherapy on T-lymphocyte subpopulations.

Authors:  R N Mshana; A Haregewoin; A Belehu
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

7.  Passive transfer of tuberculin sensitivity from anergic mice.

Authors:  I M Orme; F M Collins
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

8.  Evolution of inflammatory response and cellular immune responses in a murine model of disseminated blastomycosis.

Authors:  G S Deepe; C L Taylor; W E Bullock
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

9.  Depression by Pseudomonas aeruginosa of two T-cell-mediated responses, anti-Listeria immunity and delayed-type hypersensitivity to sheep erythrocytes.

Authors:  J C Petit; G Richard; B Albert; G L Daguet
Journal:  Infect Immun       Date:  1982-03       Impact factor: 3.441

10.  In vivo and in vitro administration of interleukin 2-containing preparation reverses T-cell unresponsiveness in Mycobacterium bovis BCG-infected mice.

Authors:  V Colizzi
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.